Agios Anticipates PK Deficiency Diagnosis Ramp-Up After Pyrukynd Approval
Reimbursement Challenges
The company hopes to grow the current diagnostic rate from 30% to 70% over two to five years. “Optimal reimbursement” for mitapivat will likely take a year, with Medicare/Medicaid lagging.
